Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine.

Krishnamurthi SS, Brell JM, Hoppel CL, Egorin MJ, Weaver KC, Li X, Ingalls ST, Zuhowski EG, Schluchter MD, Dowlati A, Cooney MM, Gibbons J, Overmoyer BA, Ivy SP, Remick SC.

Cancer Chemother Pharmacol. 2009 Feb;63(3):441-50. doi: 10.1007/s00280-008-0754-2. Epub 2008 Apr 15.

2.

Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas.

Gamblin TC, Egorin MJ, Zuhowski EG, Lagattuta TF, Herscher LL, Russo A, Libutti SK, Alexander HR, Dedrick RL, Bartlett DL.

Cancer Chemother Pharmacol. 2008 Sep;62(4):647-53. Epub 2007 Nov 27.

PMID:
18040687
3.
4.

Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study.

Bagatell R, Gore L, Egorin MJ, Ho R, Heller G, Boucher N, Zuhowski EG, Whitlock JA, Hunger SP, Narendran A, Katzenstein HM, Arceci RJ, Boklan J, Herzog CE, Whitesell L, Ivy SP, Trippett TM.

Clin Cancer Res. 2007 Mar 15;13(6):1783-8.

5.

Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers.

Ramanathan RK, Egorin MJ, Eiseman JL, Ramalingam S, Friedland D, Agarwala SS, Ivy SP, Potter DM, Chatta G, Zuhowski EG, Stoller RG, Naret C, Guo J, Belani CP.

Clin Cancer Res. 2007 Mar 15;13(6):1769-74.

7.

Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.

Abbosh PH, Montgomery JS, Starkey JA, Novotny M, Zuhowski EG, Egorin MJ, Moseman AP, Golas A, Brannon KM, Balch C, Huang TH, Nephew KP.

Cancer Res. 2006 Jun 1;66(11):5582-91.

8.

Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers.

Ramanathan RK, Trump DL, Eiseman JL, Belani CP, Agarwala SS, Zuhowski EG, Lan J, Potter DM, Ivy SP, Ramalingam S, Brufsky AM, Wong MK, Tutchko S, Egorin MJ.

Clin Cancer Res. 2005 May 1;11(9):3385-91.

9.

Role of glutathione and nucleotide excision repair in modulation of cisplatin activity with O6-benzylguanine.

Fishel ML, Gamcsik MP, Delaney SM, Zuhowski EG, Maher VM, Karrison T, Moschel RC, Egorin MJ, Dolan ME.

Cancer Chemother Pharmacol. 2005 Apr;55(4):333-342. doi: 10.1007/s00280-004-0901-3. Epub 2004 Oct 2.

PMID:
15723259
10.

Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advanced malignancies.

Chen X, Bies RR, Ramanathan RK, Zuhowski EG, Trump DL, Egorin MJ.

Cancer Chemother Pharmacol. 2005 Mar;55(3):237-43. Epub 2004 Oct 19.

PMID:
15503027
11.

Effect of cell cycle inhibition on Cisplatin-induced cytotoxicity.

Fishel ML, Newell DR, Griffin RJ, Davison R, Wang LZ, Curtin NJ, Zuhowski EG, Kasza K, Egorin MJ, Moschel RC, Dolan ME.

J Pharmacol Exp Ther. 2005 Jan;312(1):206-13. Epub 2004 Aug 10.

PMID:
15304523
12.

Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma.

Zamboni WC, Gervais AC, Egorin MJ, Schellens JH, Zuhowski EG, Pluim D, Joseph E, Hamburger DR, Working PK, Colbern G, Tonda ME, Potter DM, Eiseman JL.

Cancer Chemother Pharmacol. 2004 Apr;53(4):329-36. Epub 2003 Dec 12.

PMID:
14673619
13.

Use of high-performance liquid chromatography to characterize the rapid decomposition of wortmannin in tissue culture media.

Holleran JL, Egorin MJ, Zuhowski EG, Parise RA, Musser SM, Pan SS.

Anal Biochem. 2003 Dec 1;323(1):19-25.

PMID:
14622954
14.

Enhancement of platinum-induced cytotoxicity by O6-benzylguanine.

Fishel ML, Delaney SM, Friesen LD, Hansen RJ, Zuhowski EG, Moschel RC, Egorin MJ, Dolan ME.

Mol Cancer Ther. 2003 Jul;2(7):633-40.

15.

Biliary excretion of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) and metabolites by Fischer 344 rats.

Musser SM, Egorin MJ, Zuhowski EG, Hamburger DR, Parise RA, Covey JM, White KD, Eiseman JL.

Cancer Chemother Pharmacol. 2003 Aug;52(2):139-46. Epub 2003 May 22.

PMID:
12761648
16.

Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study.

Laufer M, Ramalingam S, Schoenberg MP, Haisfield-Wolf ME, Zuhowski EG, Trueheart IN, Eisenberger MA, Nativ O, Egorin MJ.

J Clin Oncol. 2003 Feb 15;21(4):697-703.

PMID:
12586808
17.

Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance.

Rudin CM, Yang Z, Schumaker LM, VanderWeele DJ, Newkirk K, Egorin MJ, Zuhowski EG, Cullen KJ.

Cancer Res. 2003 Jan 15;63(2):312-8.

18.

Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression.

Hershberger PA, McGuire TF, Yu WD, Zuhowski EG, Schellens JH, Egorin MJ, Trump DL, Johnson CS.

Mol Cancer Ther. 2002 Aug;1(10):821-9.

19.

Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin.

Zamboni WC, Gervais AC, Egorin MJ, Schellens JH, Hamburger DR, Delauter BJ, Grim A, Zuhowski EG, Joseph E, Pluim D, Potter DM, Eiseman JL.

Clin Cancer Res. 2002 Sep;8(9):2992-9.

20.

Pharmacokinetics of intrathecal gemcitabine in nonhuman primates.

Egorin MJ, Zuhowski EG, McCully CM, Blaney SM, Kerr JZ, Berg SL, Balis FM.

Clin Cancer Res. 2002 Jul;8(7):2437-42.

21.

Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1.

Egorin MJ, Zuhowski EG, Rosen DM, Sentz DL, Covey JM, Eiseman JL.

Cancer Chemother Pharmacol. 2001 Apr;47(4):291-302.

PMID:
11345645
22.

Phase I and pharmacokinetic study of novobiocin in combination with VP-16 in patients with refractory malignancies.

Murren JR, DiStasio SA, Lorico A, McKeon A, Zuhowski EG, Egorin MJ, Sartorelli AC, Rappa G.

Cancer J. 2000 Jul-Aug;6(4):256-65.

PMID:
11038146
23.

Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites.

Delauter BJ, Ramanathan RK, Egorin MJ, Stover LL, Zuhowski EG, Plunkett W, Zamboni WC.

Pharmacotherapy. 2000 Oct;20(10):1204-7.

PMID:
11034044
24.

Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies.

Fracasso PM, Westervelt P, Fears CL, Rosen DM, Zuhowski EG, Cazenave LA, Litchman M, Egorin MJ.

J Clin Oncol. 2000 Mar;18(5):1124-34. Erratum in: J Clin Oncol 2000 Jul;18(14):2793. Westerveldt, P [corrected to Westervelt, P]; Fears, CA [corrected to Fears, CL].

PMID:
10694566
25.

Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity.

Muldoon LL, Pagel MA, Kroll RA, Brummett RE, Doolittle ND, Zuhowski EG, Egorin MJ, Neuwelt EA.

Clin Cancer Res. 2000 Jan;6(1):309-15.

26.

Plasma pharmacokinetics and tissue distribution in CD2F1 mice of Pc4 (NSC 676418), a silicone phthalocyanine photodynamic sensitizing agent.

Egorin MJ, Zuhowski EG, Sentz DL, Dobson JM, Callery PS, Eiseman JL.

Cancer Chemother Pharmacol. 1999;44(4):283-94.

PMID:
10447575
27.

Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer.

Belani CP, Kearns CM, Zuhowski EG, Erkmen K, Hiponia D, Zacharski D, Engstrom C, Ramanathan RK, Capozzoli MJ, Aisner J, Egorin MJ.

J Clin Oncol. 1999 Feb;17(2):676-84.

PMID:
10080614
28.

A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer.

Steller MA, Egorin MJ, Trimble EL, Bartlett DL, Zuhowski EG, Alexander HR, Dedrick RL.

Cancer Chemother Pharmacol. 1999;43(2):106-14. Erratum in: Cancer Chemother Pharmacol 1999;44(1):90.

PMID:
9923815
29.

Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas.

Glantz MJ, Choy H, Kearns CM, Cole BF, Mills P, Zuhowski EG, Saris S, Rhodes CH, Stopa E, Egorin MJ.

J Clin Oncol. 1996 Feb;14(2):600-9.

PMID:
8636777
30.

Development and validation of a pharmacokinetically based fixed dosing scheme for suramin.

Reyno LM, Egorin MJ, Eisenberger MA, Sinibaldi VJ, Zuhowski EG, Sridhara R.

J Clin Oncol. 1995 Sep;13(9):2187-95.

PMID:
7666077
31.

Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer.

Eisenberger MA, Sinibaldi VJ, Reyno LM, Sridhara R, Jodrell DI, Zuhowski EG, Tkaczuk KH, Lowitt MH, Hemady RK, Jacobs SC, et al.

J Clin Oncol. 1995 Sep;13(9):2174-86.

PMID:
7666076
32.

Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors.

Glantz MJ, Choy H, Kearns CM, Mills PC, Wahlberg LU, Zuhowski EG, Calabresi P, Egorin MJ.

J Natl Cancer Inst. 1995 Jul 19;87(14):1077-81.

PMID:
7616600
33.

Rapid and sensitive high-performance liquid chromatographic assay for novobiocin in human serum.

Zuhowski EG, Gutheil JC, Egorin MJ.

J Chromatogr B Biomed Appl. 1994 Apr 22;655(1):147-52.

PMID:
8061824
34.

Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer.

Jodrell DI, Reyno LM, Sridhara R, Eisenberger MA, Tkaczuk KH, Zuhowski EG, Sinibaldi VJ, Novak MJ, Egorin MJ.

J Clin Oncol. 1994 Jan;12(1):166-75.

PMID:
8270974
35.

Suramin, an active drug for prostate cancer: interim observations in a phase I trial.

Eisenberger MA, Reyno LM, Jodrell DI, Sinibaldi VJ, Tkaczuk KH, Sridhara R, Zuhowski EG, Lowitt MH, Jacobs SC, Egorin MJ.

J Natl Cancer Inst. 1993 Apr 21;85(8):611-21. Erratum in: J Natl Cancer Inst 1994 Apr 20;86(8):639-40.

PMID:
8468719
36.

Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin.

Conley BA, Egorin MJ, Whitacre MY, Carter DC, Zuhowski EG, Van Echo DA.

Cancer Chemother Pharmacol. 1993;33(2):107-12.

PMID:
8261569
37.

Phase II trial and pharmacokinetic assessment of intravenous melphalan in patients with advanced prostate cancer.

Smith DC, Jodrell DI, Egorin MJ, Ambinder RM, Zuhowski EG, Kreis W, Ellis PG, Trump DL.

Cancer Chemother Pharmacol. 1993;31(5):363-8.

PMID:
7679331
38.

Approaches to optimal dosing of hexamethylene bisacetamide.

Conley BA, Egorin MJ, Sinibaldi V, Sewack G, Kloc C, Roberts L, Zuhowski EG, Forrest A, Van Echo DA.

Cancer Chemother Pharmacol. 1992;31(1):37-45.

PMID:
1333894
39.
40.

Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580).

Conley BA, Forrest A, Egorin MJ, Zuhowski EG, Sinibaldi V, Van Echo DA.

Cancer Res. 1989 Jun 15;49(12):3436-40.

41.

Phase I clinical and pharmacokinetic study of thiotepa administered intraperitoneally in patients with advanced malignancies.

Wadler S, Egorin MJ, Zuhowski EG, Tortorello L, Salva K, Runowicz CD, Wiernik PH.

J Clin Oncol. 1989 Jan;7(1):132-9.

PMID:
2491884
42.

Metabolism of hexamethylene bisacetamide and its metabolites in leukemic cells.

Egorin MJ, Snyder SW, Cohen AS, Zuhowski EG, Subramanyam B, Callery PS.

Cancer Res. 1988 Apr 1;48(7):1712-6.

43.

Salivary concentrations of hexamethylene bisacetamide (HMBA) in patients receiving 5-day continuous infusions.

Conley BA, Egorin MJ, Zuhowski EG, Sinibaldi VJ, Peterson DE.

Cancer Chemother Pharmacol. 1988;22(1):65-8.

PMID:
3396146
44.

Plasma pharmacokinetics and urinary excretion of hexamethylene bisacetamide metabolites.

Egorin MJ, Zuhowski EG, Cohen AS, Geelhaar LA, Callery PS, Van Echo DA.

Cancer Res. 1987 Nov 15;47(22):6142-6.

45.

Phase I study and pharmacokinetics of menogaril (NSC 269148) in patients with hepatic dysfunction.

Egorin MJ, Conley BA, Forrest A, Zuhowski EG, Sinibaldi V, Van Echo DA.

Cancer Res. 1987 Nov 15;47(22):6104-10.

46.

Gas chromatographic analysis of metabolites of the cell differentiating agent hexamethylene bisacetamide.

Egorin MJ, Zuhowski EG, Nayar MS, Callery PS.

J Chromatogr. 1987 Mar 20;415(1):148-55. No abstract available.

PMID:
3584350
47.

Supplemental Content

Loading ...
Support Center